Can biomarkers be used to improve diagnosis and prediction of metabolic syndrome in childhood cancer survivors? A systematic review

Summary Childhood cancer survivors (CCS) are at increased risk to develop metabolic syndrome (MetS), diabetes, and cardiovascular disease. Common criteria underestimate adiposity and possibly underdiagnose MetS, particularly after abdominal radiotherapy. A systematic literature review and meta‐analy...

Full description

Saved in:
Bibliographic Details
Published inObesity reviews Vol. 22; no. 11; pp. e13312 - n/a
Main Authors Pluimakers, Vincent G., Santen, Selveta S., Fiocco, Marta, Bakker, Marie‐Christine E., Lelij, Aart J., Heuvel‐Eibrink, Marry M., Neggers, Sebastian J. C. M. M.
Format Journal Article
LanguageEnglish
Published England Wiley Subscription Services, Inc 01.11.2021
John Wiley and Sons Inc
Subjects
Online AccessGet full text
ISSN1467-7881
1467-789X
1467-789X
DOI10.1111/obr.13312

Cover

More Information
Summary:Summary Childhood cancer survivors (CCS) are at increased risk to develop metabolic syndrome (MetS), diabetes, and cardiovascular disease. Common criteria underestimate adiposity and possibly underdiagnose MetS, particularly after abdominal radiotherapy. A systematic literature review and meta‐analysis on the diagnostic and predictive value of nine newer MetS related biomarkers (adiponectin, leptin, uric acid, hsCRP, TNF‐alpha, IL‐1, IL‐6, apolipoprotein B (apoB), and lipoprotein(a) [lp(a)]) in survivors and adult non‐cancer survivors was performed by searching PubMed and Embase. Evidence was summarized with GRADE after risk of bias evaluation (QUADAS‐2/QUIPS). Eligible studies on promising biomarkers were pooled. We identified 175 general population and five CCS studies. In the general population, valuable predictive biomarkers are uric acid, adiponectin, hsCRP and apoB (high level of evidence), and leptin (moderate level of evidence). Valuable diagnostic biomarkers are hsCRP, adiponectin, uric acid, and leptin (low, low, moderate, and high level of evidence, respectively). Meta‐analysis showed OR for hyperuricemia of 2.94 (age‐/sex‐adjusted), OR per unit uric acid increase of 1.086 (unadjusted), and AUC for hsCRP of 0.71 (unadjusted). Uric acid, adiponectin, hsCRP, leptin, and apoB can be alternative biomarkers in the screening setting for MetS in survivors, to enhance early identification of those at high risk of subsequent complications.
Bibliography:Funding information
Vincent G. Pluimakers, Selveta S. van Santen, Marry M. van den Heuvel‐Eibrink, and Sebastian J.C.M.M. Neggers contributed equally to the content of this manuscript
Erasmus Medisch Centrum; Princess Máxima Center for Pediatric Oncology
ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
Funding information Erasmus Medisch Centrum; Princess Máxima Center for Pediatric Oncology
ISSN:1467-7881
1467-789X
1467-789X
DOI:10.1111/obr.13312